Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals
- PMID: 27400930
- PMCID: PMC5226942
- DOI: 10.1007/s13365-016-0466-z
Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals
Abstract
HIV-associated neurocognitive disorders (HANDs) continue to be common and are associated with increased morbidity and mortality. However, the underlying mechanisms in the combination antiretroviral therapy (cART) era are not fully understood. Interferon alpha (IFNα) is an antiviral cytokine found to be elevated in the cerebrospinal fluid (CSF) of individuals with advanced HIV-associated dementia in the pre-cART era. In this cross-sectional study, we investigated the association between IFNα and neurocognitive performance in ambulatory HIV-infected individuals with milder impairment. An eight-test neuropsychological battery representing six cognitive domains was administered. Individual scores were adjusted for demographic characteristics, and a composite neuropsychological score (NPT-8) was calculated. IFNα and CSF neurofilament light chain (NFL) levels were measured using enzyme-linked immunosorbent assay (ELISA). There were 15 chronically infected participants with a history of significant immunocompromise (median nadir CD4+ of 49 cells/μl). Most participants were neurocognitively impaired (mean global deficit score of 0.86). CSF IFNα negatively correlated with three individual tests (Trailmaking A, Trailmaking B, and Stroop Color-Word) as well as the composite NPT-8 score (r = -0.67, p = 0.006). These negative correlations persisted in multivariable analyses adjusting for chronic hepatitis B and C. Additionally, CSF IFNα correlated strongly with CSF NFL, a marker of neuronal damage (rho = 0.748, p = 0.0013). These results extend findings from individuals with severe HIV-associated dementia in the pre-cART era and suggest that IFNα may continue to play a role in HAND pathogenesis during the cART era. Further investigation into the role of IFNα is indicated.
Keywords: Aids; HIV; Interferon alpha; Memory disorders.
Conflict of interest statement
Figures
Similar articles
-
Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.J Neurovirol. 2015 Aug;21(4):439-48. doi: 10.1007/s13365-015-0333-3. Epub 2015 Mar 17. J Neurovirol. 2015. PMID: 25776526 Free PMC article.
-
A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.J Neurovirol. 2017 Apr;23(2):216-225. doi: 10.1007/s13365-016-0490-z. Epub 2016 Nov 4. J Neurovirol. 2017. PMID: 27815816
-
Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.AIDS. 2019 Mar 15;33(4):615-625. doi: 10.1097/QAD.0000000000002121. AIDS. 2019. PMID: 30557159 Free PMC article.
-
Diagnostic and prognostic biomarkers for HAND.J Neurovirol. 2019 Oct;25(5):686-701. doi: 10.1007/s13365-018-0705-6. Epub 2019 Jan 3. J Neurovirol. 2019. PMID: 30607890 Free PMC article. Review.
-
HIV-1 infection and cognitive impairment in the cART era: a review.AIDS. 2011 Mar 13;25(5):561-75. doi: 10.1097/QAD.0b013e3283437f9a. AIDS. 2011. PMID: 21160410 Review.
Cited by
-
Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection.J Neuroinflammation. 2018 Mar 6;15(1):70. doi: 10.1186/s12974-018-1102-z. J Neuroinflammation. 2018. PMID: 29510721 Free PMC article.
-
Breaking down the cellular responses to type I interferon neurotoxicity in the brain.Front Immunol. 2023 Feb 3;14:1110593. doi: 10.3389/fimmu.2023.1110593. eCollection 2023. Front Immunol. 2023. PMID: 36817430 Free PMC article. Review.
-
Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.J Neuroimmune Pharmacol. 2020 Dec;15(4):780-793. doi: 10.1007/s11481-020-09918-7. Epub 2020 May 14. J Neuroimmune Pharmacol. 2020. PMID: 32409991 Free PMC article. Review.
-
Type I Interferons in NeuroHIV.Viral Immunol. 2019 Jan/Feb;32(1):7-14. doi: 10.1089/vim.2018.0085. Epub 2018 Sep 27. Viral Immunol. 2019. PMID: 30260742 Free PMC article. Review.
-
Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder.Sci Rep. 2019 Jun 19;9(1):8733. doi: 10.1038/s41598-019-45418-2. Sci Rep. 2019. PMID: 31217522 Free PMC article.
References
-
- Abbott RJ, Bolderson I, Gruer PJ. Assessment of an immunoassay for interferon-alpha in cerebrospinal fluid as a diagnostic aid in infections of the central nervous system. J Infect. 1987;15:153–60. - PubMed
-
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99. - PMC - PubMed
-
- Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK, Group H. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307–19. - PubMed
-
- Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ. APOE epsilon4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. BMC Neurol. 2015;15:51. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials